RemovedRisk Factors
December 31, 2024, our cash flow used for debt service totaled $184.9 million, which was comprised of $5.0 million of principal payments on the Term Loan (as defined herein) and interest payments of $179.9 million on all of our outstanding debt.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Term SOFR and certain other interest “benchmarks” are subject to regulatory guidance and reform that we expect will cause interest rates under our current or future debt agreements to perform differently than in the past or could cause other unanticipated consequences.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Because our Senior Secured Credit Facilities bear interest at variable interest rates, based on the Term SOFR and certain other interest “benchmarks,” fluctuations in interest rates could have a material effect on our business. We currently utilize, and may in the future utilize, derivative financial instruments such as interest rate swaps or interest rate caps to hedge some of our exposure to interest rate fluctuations, but such instruments may not be effective in reducing our exposure to interest fluctuations, and we may discontinue utilizing them at any time. As a result, we may incur higher interest costs if interest rates increase. These higher interest costs could have a material adverse impact on our financial condition and the levels of cash we maintain for working capital.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
As of February 20, 2025, the Sponsors own approximately 43.4% of our outstanding common stock and retain the right to designate over a majority of our directors. The Stockholders Agreement contains agreements with respect to certain other matters, including the election of directors; mergers, consolidations and acquisitions; the sale of all or substantially all of our
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Stockholders Agreement and (ii) the number of directors shall not exceed eleven without the consent of Warburg Pincus or GTCR;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•providing that for so long as investment funds and entities affiliated with either Warburg Pincus or GTCR have the right (individually) to designate at least three directors for election to our board of directors, certain board approvals, including amendments to our Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws and certain specified corporate transactions, including certain acquisitions, mergers, other business combination transactions and dispositions, may be effected only with the affirmative vote of 75% of our board of directors, in addition to any other vote required by applicable law;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
Any disruption in the availability of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of current geopolitical instability against Russia by the United States, Canada, the United Kingdom, and and/or the European Union, or sanctions by Russia against those countries, may have a material adverse effect on our operating results.” and “—We conduct sales and distribution operations on a worldwide basis and are subject to a variety of risks associated with doing business outside the United States.”
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The conflict between Israel and Hamas and Hamas’ allies, including Iran and factions in Lebanon, and its potential ramifications for the Middle East Geopolitical conflicts have caused and and, in the future, may continue to cause instability and volatility in global markets and adversely impact global supply chains, including potentially disrupting shipping channels.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we and other organizations disagree with the US EPA’s assessments of the carcinogenic potency of EO, Sterigenics’ facilities and other EO facilities could continue to be the subject of unfavorable air quality assessments, regulations and other initiatives as risk assessments of EO continue to evolve.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In March 2024, the US EPA announced final rules under NESHAP the National Emissions Standards for Hazardous Air Pollutants (“NESHAP”) to govern EO sterilization facilities in the United States. States, and on April 5, 2024, the final NESHAP regulation became effective.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, in the past, following periods of volatility in the overall market and the market price of companies’ securities, securities class action litigation has often been instituted against these companies, and we have been named as a defendant in such a putative securities class action of this kind that was dismissed at the trial court level and is currently pending against us. on appeal.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Material increases in the price of labor, raw materials, or energy could have a material adverse effect on our business, prospects, financial condition or results of operations, particularly if we are unable to increase the prices to our customers of our products or services to offset inflationary cost trends or if we are unable to achieve cost savings to offset such cost increases, our profits and operating results could be adversely affected. trends.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In 2016, the US EPA published its Integrated Risk Information System toxicity assessment of EO (the “2016 IRIS Assessment”), and, since 2018, the US EPA has published National Air Toxics Assessments, which have been succeeded by Air Toxics Screening Assessments.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, although EO is present in the environment from a variety of sources and naturally produced by the human body, the US EPA has identified a potential for increased risk of certain cancers from exposure to EO emitted from sterilization facilities.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Grand Prairie, Texas; and Vernon, California and may be filed in the future relating to these or Sterigenics’ other EO facilities; these These threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Grand Prairie, Texas; and Vernon, California Additional EO lawsuits have been threatened and may be filed in the future relating to these or Sterigenics’ other our EO facilities; facilities in the United States; these threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The potential worsening of macro-economic conditions, including changes in tariff and trade policies, slower growth or recession, recessionary conditions, the inflationary environment, tighter credit, higher high interest rates and currency fluctuations, may cause customers to modify, delay or cancel plans to purchase our products and services and suppliers may significantly and rapidly increase their prices or reduce their output because of cash flow problems.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In 2016, the US EPA published its Integrated Risk Information System toxicity assessment of EO (the “2016 IRIS Assessment”), and, since 2018, the US EPA has published National Air Toxics Assessments, which have been succeeded by Air Toxics Screening Assessments. U.S.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our business is highly competitive, and if we fail to compete successfully, our business, prospects, financial condition or results of operations may be materially adversely affected.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Most of our customer contracts for sterilization services allow us to pass through our all direct material costs, but we may not be able to immediately or completely implement increases in the prices of our products and services.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If similarly severe global health crises occur in the future, the impact and effects on our business, operations and results of operations could also could be material.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may incur impairment charges on our goodwill and other intangible assets with indefinite lives as well as other long-lived assets and intangible assets with definite lives, which could negatively impact adversely affect our business, financial condition or results of operations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
On September 17, 2025, the Company and SHH entered into Amendment No. 6 to the Credit Agreement. Amendment No. 6 reduced the interest rate to Adjusted Term SOFR (as defined in the Credit Agreement) plus 2.50%, with a 0.00% floor.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•Litigation costs. On April 3, 2025 and July 23, 2025, Sterigenics entered into binding term sheets to resolve 97 and 129 EO claims, respectively, against Sterigenics relating to its former facility in Willowbrook, Illinois. Pursuant to the term sheets, Sterigenics agreed to pay $30.9 million and $34.0 million, respectively, allowing for the settling plaintiffs’ claims to be dismissed with prejudice.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Amortization of intangible assets primarily consists of expense associated with customer relationship, proprietary technology, trade names and other intangible assets. Amortization expense fluctuates when we have an acquisition, disposition, impairment charge, or as asset useful lives expire.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The following represents the costs related to EO litigation settlement agreements:
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
(d)Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Under the debt agreements summarized below, at December 31, 2025 we and SHH, our wholly owned subsidiary, had debt payment obligations under (a) a term loan in the amount of $1,419.5 million, (b) a revolving credit facility, which supported operationally-related letters of credit but was otherwise undrawn, and which provides to us capacity up to $600.0 million for future potential borrowings, and (c) $750.0 million of senior secured notes. Our debt agreements also include additional covenants, conditions and rights to request additional debt, as summarized below.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The Company and SHH had previously entered into Amendment No. 4 to the Credit Agreement on May 30, 2024, respectively. See Note 9, “Long-Term Debt” to the Financial Statements for a description of this amendment.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The Senior Secured Credit Facilities and the Indenture contain certain covenants and events of default. Additionally, all of SHH’s obligations under the Senior Secured Credit Facilities and the Indenture are unconditionally guaranteed by the Company and certain domestic restricted subsidiaries. For additional information about our Senior Secured Credit Facilities, the Indenture and the Secured Notes, including the covenants and events of default, refer to Note 8, “Long-Term Debt,” to our Financial Statements.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
We are a trusted partner to approximately 5,000 customers in over 50 countries. We strive to give our customers confidence that their products meet regulatory, safety and effectiveness requirements. With our industry-recognized scientific and technological expertise, we help to promote the safety of millions of patients and healthcare practitioners around the world every year. Across our 62 facilities worldwide, we have over 3,000 employees who are dedicated to safety and quality.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
As discussed in Item 1A, “Risk Factors”, a portion of our supply of Co-60 is generated by Russian nuclear reactors. We continue to monitor the potential for disruption in the supply of Co-60 from Russian nuclear reactors. There was no impact to our supply or revenue in the year ended December 31, 2024.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•Litigation costs. We are currently the subject of tort lawsuits alleging injury by purported exposure to EO used, emitted or released by current facilities in Atlanta, Georgia and Vernon, California and our former facility in Willowbrook, Illinois. Additional EO lawsuits have been threatened relating to Sterigenics’ former facility in Willowbrook and existing facilities in Atlanta, Georgia; Charlotte, North Carolina; Grand Prairie, Texas; and Vernon, California and may be filed in the future relating to these or Sterigenics’ other EO facilities; these threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry. In addition, we are defendants in a lawsuit brought by the State of New Mexico Attorney General alleging that emissions of EO from our Santa Teresa facility negatively impacted Santa Teresa and surrounding communities. We maintain that these facilities did not pose and do not pose any safety risk to their surrounding communities. We deny the allegations in these lawsuits and are vigorously defending against these claims. See Item 3, “Legal Proceedings” and Note 19, “Commitments and Contingencies,” to our consolidated financial statements.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•Borrowings, financing costs and financial leverage. On May 30, 2024, the Company and SHH entered into Amendment No. 4 to the Senior Secured Credit Facilities, which provided for the issuance of term loans to the Company in an aggregate principal amount of $1,509.4 million maturing on May 30, 2031. On the same date, the Company issued Secured Notes in an aggregate principal amount of $750.0 million, which bear interest at an annual rate of 7.375% and mature on June 1, 2031. The proceeds from the Refinancing Term Loans and the issuance of the Secured Notes, along with cash on the balance sheet, were used to refinance all of the Company’s previously outstanding term loans due December 2026.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Amortization of intangible assets primarily consists of expense associated with customer relationship intangible assets, the majority of which relate to the fair values attributed to these assets upon the recapitalization of the Company in connection with the acquisition by the Sponsors in 2015. These customer relationship intangible assets were initially assigned a weighted average useful life of ten years and have a remaining useful life of approximately one year. These customer relationship intangible assets accounted for approximately $48.4 million of our current annual amortization expense and are expected to be fully amortized in 2025. Amortization expense fluctuates when we have an acquisition, disposition, impairment charge, or as their useful lives expire.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Operating income represents gross profit, less SG&A and amortization of intangible assets.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
During the year ended December 31, 2022, we recorded an impairment charge of $9.6 million related to a joint venture investment, which was acquired as part of the 2020 acquisition of Iotron Industries Canada, Inc.. Due to a shift in business strategy, the joint venture did not proceed. Based on these facts and circumstances, we concluded that the investment was impaired as of June 30, 2022.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(thousands of U.S. dollars) 2024 2023 $ Change % Change Operating expenses for the year ended December 31, Selling, general and administrative expenses $242,630 $236,667 $5,963 2.5% Amortization of intangible assets 62,039 63,799 (1,760) (2.8)% Total operating expenses $304,669 $300,466 $4,203 1.4%
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(d)Represents (i) certain costs related to acquisitions and the integration of recent acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018, (iv) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (v) professional fees, payroll costs, and other costs, including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility. The year ended December 31, 2023 includes a $1.0 million cancellation fee received from a tenant in connection with the termination of an office space lease at the Nordion facility.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
(j)Interest expense, net presented in this reconciliation for the year ended December 31, 2023 has been adjusted to conform to the current year presentation to include interest expense, net on Term Loan B due 2026 attributable to the loan proceeds that were used to fund the $408.0 million Illinois EO litigation settlement.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
As described in more detail below, on March 1, 2024, the Company and SHH entered into Amendment No. 3 to the Revolving Credit Facility. Amendment No. 3 did not materially change the terms and conditions of the Credit Agreement, including
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
with respect to the amount of commitments under the Revolving Credit Facility, which remain $423.8 million.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in thousands) 2025 2024 2023 Net income $ 77,949 $ 44,398 $ 51,376 Amortization of intangible assets 41,798 79,377 81,348 Share-based compensation(a) 31,068 36,896 32,364 Loss on refinancing of debt(b) 1,462 24,168 — Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net(c) 58 2,448 (1,552) Business optimization expenses(d) 7,504 7,662 8,068 9,368 Professional services relating to EO sterilization facilities(e) 46,225 32,694 45,312 Georgia Illinois EO litigation settlement(f) — 35,000 Secondary offering and other shareholder activities(g) 1,864 settlements(f) 64,943 — Accretion of asset retirement obligations(h) obligations(g) 2,321 2,638 2,413 Income tax benefit associated with pre-tax adjustments(i) adjustments(h) (28,478) (33,487) (49,597) Adjusted Net Income 245,414 198,500 204,326 Interest expense, net(j) net 155,722 164,691 142,878 Depreciation(k) Depreciation(i) 94,630 82,420 76,577 Income tax provision applicable to Adjusted Net Income(l) Income(j) 98,035 102,963 104,248 Adjusted EBITDA(m) EBITDA(k) $ 593,801 $ 548,574 $ 528,029
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Among other changes, Amendment No. 3 5 provides (i) for new an increase in the commitments under the existing Revolving Credit Facility to replace the existing revolving commitments in an aggregate principal amount of $83.0 million, Facility, (ii) that certain of the lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $37.5 million and (iii) for the extension of extends the maturity date of the Revolving Credit Facility to March 1, 2029. April 30, 2030.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in cash and cash equivalents was attributable to $179.0 million of purchases of property, plant and equipment, $50.6 $287.2 million of cash used in financing provided by operating activities and a $17.4 $16.1 million decline increase due to favorable changes in foreign currency exchange rates, partially offset by $224.2 $138.0 million of purchases of property, plant and equipment and $100.5 million of cash provided by operating used in financing activities.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Among other changes, Amendment No. 4 6 provides for Refinancing the refinancing lenders to provide term loans (the “Repriced Term Loans Loans”) to SHH in an aggregate principal amount of $1,509.4 million. $1,419.5 million, which reflects the balance after the Company’s application of $75.0 million of available cash to repay outstanding borrowings under its term loan facility.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in net cash provided by operating activities in 2024 the year ended December 31, 2025 compared to the prior year was due mainly to the timing of a $43.2 million increase in gross profit, a $15.9 million decrease in cash outflows paid for the Illinois interest and Georgia EO litigation settlements. a $5.0 million decrease in cash paid for income taxes.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Provision for income taxes for the year ended December 31, 2024 2025 differed from the statutory rate of 21% primarily due to a net increase recognition of the cumulative tax effects of the change in U.S. income tax laws under the OBBBA associated with the accounting for the valuation allowance attributable to the limitation on the deductibility of interest expense and the foreign rate expense.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Product revenues increased $14.9 $9.2 million, or 10.4%, 5.8%, to $167.9 million in the year ended December 31, 2025 as compared to $158.6 million in the year ended December 31, 2024 as compared to $143.7 million in the year ended December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The This refinancing activity primarily resulted in the write off of certain unamortized debt issuance costs and discounts on the Term Loans due 2026. 2026 and the expensing of certain new debt issuance costs and discounts upon the issuance of the Refinancing Term Loans (as defined below) and Secured Notes.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
For In addition, for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, we recorded costs of $46.2 million, $32.7 million, $45.3 million and $72.6 $45.3 million, respectively, representing of litigation and other professional fees and other expenses related to litigation associated with our EO sterilization facilities.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Other income, net primarily consists of changes in the fair value of the embedded derivatives in Nordion’s contracts, contracts and the net impact of pension related benefits and the income related to deferred income on a lease associated with the 2018 divestiture of the Medical Isotopes business. pension-related benefits.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Among other changes, Amendment No. 3 5 provides (i) for new an increase in the commitments under the existing Revolving Credit Facility to replace the existing revolving commitments in an aggregate principal amount of $83.0 million, $176.2 million (ii) that certain of the lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $37.5 $186.3 million and (iii) for the extension of the maturity date of the Revolving Credit Facility to March 1, 2029. April 30, 2030.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Adjusted Net Income was $245.4 million for the year ended December 31, 2025, as compared to $198.5 million for the year ended December 31, 2024, as compared to $204.3 million for the year ended December 31, 2023, primarily due to the factors described above.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
Costs associated with support functions that are not directly associated with one of the three reportable segments, such as corporate operating expenses for executive management, accounting, information technology, legal, human resources, treasury, investor relations, corporate development, tax, purchasing, and marketing, are allocated to the segments primarily based on net revenue.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new